P Ruggenenti, I Iliev, GM Costa, A Parvanova, A … - Diabetes Care, 2008 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—This prespecified study compared the incidence of
ECG-LVH by Sokolow-Lyon and Cornell voltage criteria in 816 hypertensive type 2 diabetic patients
of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT), who had no ECG- ... Cited by 3 - Related articles - All 5 versions
C Cuspidi, F Negri, A Zanchetti - Vascular Health and Risk …, 2008 - pubmedcentral.nih.gov Left ventricular hypertrophy (LVH) and atrial fibrillation (AF) are strong predictors of cardiovascular
(CV) morbidity and mortality, independently of blood pressure levels and other modifiable and
nonmodifiable risk factors. The actions of circulating and tissue angiotensin II, mediated ... Cited by 3 - Related articles - BL Direct - All 7 versions
DSC Ang, TP Fahey, GA Wright, AD Struthers - American Journal of …, 2008 - nature.com The prevalence of echo LVH in both patient cohorts was 50%. Six independent predictors of
LVH were identified in the development cohort: age >65 years (1 point), body mass index >30
kg/m 2 (1 point), history of hypertension (1 point), previous myocardial infarction (1 point), ... Cited by 2 - Related articles - All 3 versions
DSC Ang, CC Lang - Journal of Human Hypertension, 2008 - nature.com In hypertension, the presence of left ventricular hypertrophy (LVH) is associated with increased
risk of both cardiovascular morbidity and mortality. To date, the electrocardiogram (ECG) remains
the cornerstone of LVH diagnosis in clinical practice because it is universally available, ... Cited by 3 - Related articles - All 3 versions
V Barrios, C Escobar, A Calderón, L Ribas, D … - Blood …, 2008 - informahealthcare.com Introduction. Detection and treatment of left ventricular hypertrophy (LVH) in hypertension is important
in order to reduce cardiovascular risk. The product of QRS voltage and duration (eg Cornell
voltage‐duration product; CorP), is a good marker of LVH and the current study was ... Cited by 4 - Related articles - All 5 versions
MD Piero Ruggenenti, MD Ilian Iliev, MD Grazia Maria … - Am Diabetes Assoc *°Piero Ruggenenti MD, *Ilian Iliev MD, *^Grazia Maria Costa MD, *Aneliya Parvanova MD,
*Annalisa Perna Stat Sci D, *Giovanni Antonio Giuliano Dipl Stat, *Nicola Motterlini Stat Sci
D, *Bogdan Ene-Iordache Eng D, *°Giuseppe Remuzzi MD, FRCP, and the BENEDICT ... Related articles - All 2 versions
SD Pierdomenico, D Lapenna, F Cuccurullo - American Journal of …, 2008 - nature.com There is still ambiguity about the prognostic relevance of regression of left ventricular hypertrophy
(LVH) (as revealed by echocardiography) in a large population of subjects with
hypertension, with and without evidence of LVH in their electrocardiograms (ECGs). This ... Cited by 7 - Related articles - All 2 versions
[CITATION] Comparative antihypertensive efficacy of the oral direct renin inhibitor aliskiren, …
P Palatini, W Jung, E Shlyakhto, J Botha, M Bheda, DL … - J. Am. Coll. Cardiol, 2008 Cited by 3 - Related articles
BH Oh - Expert Opin. Pharmacother., 2007 - informahealthcare.com Aliskiren, the direct renin inhibitor, is the first new class of drug available in 13 years for the treatment
of hypertension. Renin has long been recognized as a preferred site for blockade of the
renin-angiotensin-aldosterone system because it prevents conversion of ... Cited by 8 - Related articles - BL Direct - All 7 versions
- ►ahajournals.org I Os, V Franco, SE Kjeldsen, K Manhem, RB Devereux, … - Hypertension, 2008 - Am Heart Assoc Hypertension is a risk factor for cardiovascular disease and outcomes in women. These posthoc
analyses from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study
evaluated losartan- versus atenolol-based therapy on the primary composite end point of ... Cited by 15 - Related articles - All 6 versions
